Benjamin M. Greenberg, MD, MHS / Professor Anthony Traboulsee, MD - Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

58:32
 
Jaa
 

Manage episode 334837860 series 9881
Tekijältä PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Player FM:n ja yhteisömme löytämä — tekijänoikeuksien omistajana on kustantaja eikä Player FM ja ääntä lähetetään suoraan heidän palvelimiltaan. Napsauta Tilaa -painiketta, kun haluat seurata Player FM:n päivityksiä tai liittää syötteen URL-osoitteen muihin podcast-sovelluksiin.
Go online to PeerView.com/DTJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors show great promise in the quest to identify additional novel interventions to address multiple sclerosis (MS) pathophysiology and help to individualize care. Four BTK inhibitors—evobrutinib, tolebrutinib, fenebrutinib, and remibrutinib—are in phase 3 clinical trials for relapsing and/or progressive MS, based on the potential of these agents to affect processes mediated by B cells and myeloid cells (eg, microglia), which may contribute to inflammation and neurodegeneration. At a recent live CME/NCPD/CPE event, a panel of expert physicians highlighted the rationale for using BTK inhibitors to treat MS, assessed the latest data from completed and ongoing clinical trials, and reviewed guideline-recommended protocols for patient imaging. In addition to the lively discussion, animated video abstracts further illustrated these topics. Upon completion of this activity, participants should be better able to: Describe the rationale for inhibiting Bruton tyrosine kinase (BTK) to treat multiple sclerosis (MS); Evaluate current evidence related to the efficacy, safety, and tolerability of BTK inhibitors in the treatment of MS; Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities; and Implement guideline-recommended imaging protocols to assess disease activity and monitor treatment response in patients with MS.

190 jaksoa